TG Therapeutics/$TGTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About TG Therapeutics
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
Ticker
$TGTX
Sector
Primary listing
Employees
370
Headquarters
Website
TG Therapeutics Metrics
BasicAdvanced
$5.1B
96.10
$0.36
1.95
-
Price and volume
Market cap
$5.1B
Beta
1.95
52-week high
$46.48
52-week low
$22.61
Average daily volume
1.8M
Financial strength
Current ratio
3.863
Quick ratio
2.812
Long term debt to equity
91.388
Total debt to equity
92.075
Interest coverage (TTM)
2.75%
Profitability
EBITDA (TTM)
85.884
Gross margin (TTM)
86.96%
Net profit margin (TTM)
13.31%
Operating margin (TTM)
18.91%
Effective tax rate (TTM)
8.55%
Revenue per employee (TTM)
$1,230,000
Management effectiveness
Return on assets (TTM)
9.72%
Return on equity (TTM)
26.63%
Valuation
Price to earnings (TTM)
96.104
Price to revenue (TTM)
11.143
Price to book
21.22
Price to tangible book (TTM)
18.22
Price to free cash flow (TTM)
-85.415
Free cash flow yield (TTM)
-1.17%
Free cash flow per share (TTM)
-0.406
Growth
Revenue change (TTM)
30.96%
Earnings per share change (TTM)
-43.55%
3-year revenue growth (CAGR)
302.55%
10-year revenue growth (CAGR)
122.55%
3-year earnings per share growth (CAGR)
-44.94%
10-year earnings per share growth (CAGR)
-14.37%
What the Analysts think about TG Therapeutics
Analyst ratings (Buy, Hold, Sell) for TG Therapeutics stock.
Bulls say / Bears say
BRIUMVI U.S. net revenue grew 91% year-over-year to $138.8 million in Q2 2025, driving management to raise full-year 2025 BRIUMVI revenue guidance to $570 – $575 million (Nasdaq)
TG Therapeutics has advanced its pipeline by initiating patient enrollment in the Phase 3 ENHANCE trial for a consolidated Day 1/Day 15 IV dosing regimen of BRIUMVI and dosed the first progressive MS patient in its Phase 1 azer-cel study, underpinning future growth potential (Ainvest)
The company secured three additional U.S. patents for BRIUMVI in Q1 2025, extending patent exclusivity through 2042 and mitigating the risk of generic competition for nearly two decades (Zacks)
TG Therapeutics’ revenue remains highly concentrated in a single product, with BRIUMVI U.S. net sales accounting for approximately 98.4% of total Q2 2025 revenue, exposing the company to significant risk if competitors gain share or if safety/tolerability issues emerge (Nasdaq)
Operating expenses rose sharply in Q2 2025, with R&D spending up 80.7% and SG&A costs up 43.3% year-over-year, compressing margins and contributing to an adjusted EPS miss despite strong sales (Nasdaq)
TG Therapeutics’ stock plunged 18% following the Q2 2025 earnings release after the company missed EPS forecasts by four cents despite beating revenue expectations, highlighting investor sensitivity to profitability over top-line growth (Investor’s Business Daily)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.
TG Therapeutics Financial Performance
Revenues and expenses
TG Therapeutics Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for TG Therapeutics stock?
TG Therapeutics (TGTX) has a market cap of $5.1B as of October 20, 2025.
What is the P/E ratio for TG Therapeutics stock?
The price to earnings (P/E) ratio for TG Therapeutics (TGTX) stock is 96.1 as of October 20, 2025.
Does TG Therapeutics stock pay dividends?
No, TG Therapeutics (TGTX) stock does not pay dividends to its shareholders as of October 20, 2025.
When is the next TG Therapeutics dividend payment date?
TG Therapeutics (TGTX) stock does not pay dividends to its shareholders.
What is the beta indicator for TG Therapeutics?
TG Therapeutics (TGTX) has a beta rating of 1.95. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.